Payment overview · 2025
General Payments
$854.29
47 reported records · 14 companies
Healthcare provider profile · identity verified
David Kavtaradze, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · CORDELE, GA · NPI 1376516484
Verified facts
What the public records show
CMS Open Payments records show David Kavtaradze, M.D. received $854.29 in general payments during 2025 across 47 reported records.
AstraZeneca Pharmaceuticals LP accounted for 37.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Gemtesa, Jardiance, Kerendia, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 284 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 570 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 797 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 481 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 606 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $322.76 | 37.8% | 19 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $121.26 | 14.2% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $73.33 | 8.6% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $65.57 | 7.7% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $61.12 | 7.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $56.20 | 6.6% | 3 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $41.99 | 4.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.27 | 2.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.28 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.30 | 2.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.86 | 2.0% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $16.52 | 1.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.10 | 1.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $7.73 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $854.29 | 47 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $146.89 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $117.34 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $100.57 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $76.68 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $73.33 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $65.57 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $61.12 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $56.20 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $56.20 | 3 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $41.99 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $30.96 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.30 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $16.52 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $7.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 65 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 606 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 570 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 167 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 85 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 211 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 481 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 797 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
284 | 58 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
570 | 98 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
75 | 17 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
85 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
13 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
797 | 153 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
167 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
211 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
481 | 82 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
606 | 100 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1609 | 272 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1596 | 247 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1437 | 241 |
| Carvedilol | Carvedilol | 1322 | 189 |
| Gabapentin | Gabapentin | 1232 | 190 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1075 | 154 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 953 | 114 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 797 | 153 |
| Trazodone Hcl | Trazodone Hcl | 775 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 772 | 130 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 729 | 145 |
| Clopidogrel | Clopidogrel Bisulfate | 709 | 118 |
| Potassium Chloride | Potassium Chloride | 679 | 111 |
| Furosemide | Furosemide | 667 | 126 |
| Hydrochlorothiazide | Hydrochlorothiazide | 607 | 115 |
| Eliquis | Apixaban | 606 | 100 |
| Lisinopril | Lisinopril | 596 | 110 |
| Metformin Hcl | Metformin Hcl | 595 | 128 |
| Farxiga | Dapagliflozin Propanediol | 570 | 98 |
| Duloxetine Hcl | Duloxetine Hcl | 483 | 59 |
| Ozempic | Semaglutide | 481 | 82 |
| Losartan Potassium | Losartan Potassium | 453 | 79 |
| Simvastatin | Simvastatin | 449 | 75 |
| Metoprolol Tartrate | Metoprolol Tartrate | 447 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 407 | 66 |
| Omeprazole | Omeprazole | 405 | 80 |
| Meloxicam | Meloxicam | 381 | 64 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 369 | 67 |
| Allopurinol | Allopurinol | 358 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 331 | 71 |
| Fluoxetine Hcl | Fluoxetine Hcl | 331 | 60 |
| Levetiracetam | Levetiracetam | 324 | 33 |
| Pregabalin | Pregabalin | 311 | 59 |
| Memantine Hcl | Memantine Hcl | 303 | 45 |
| Tizanidine Hcl | Tizanidine Hcl | 302 | 63 |
| Tramadol Hcl | Tramadol Hcl | 291 | 60 |
| Linzess | Linaclotide | 284 | 58 |
| Sertraline Hcl | Sertraline Hcl | 284 | 52 |
| Oxycodone Hcl | Oxycodone Hcl | 282 | 35 |
| Methylprednisolone | Methylprednisolone | 266 | 171 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 254 | 53 |
| Montelukast Sodium | Montelukast Sodium | 241 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 233 | 56 |
| Hydralazine Hcl | Hydralazine Hcl | 232 | 42 |
| Lorazepam | Lorazepam | 228 | 42 |
| Donepezil Hcl | Donepezil Hcl | 225 | 34 |
| Mounjaro | Tirzepatide | 211 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 203 | 42 |
| Alprazolam | Alprazolam | 200 | 26 |
| Famotidine | Famotidine | 200 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 200 | 41 |
| Azithromycin | Azithromycin | 199 | 157 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 190 | 49 |
| Ezetimibe | Ezetimibe | 181 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 178 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 177 | 23 |
| Clonazepam | Clonazepam | 175 | 21 |
| Myrbetriq | Mirabegron | 175 | 21 |
| Jardiance | Empagliflozin | 167 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 166 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 162 | 33 |
| Prednisone | Prednisone | 151 | 51 |
| Raloxifene Hcl | Raloxifene Hcl | 151 | 40 |
| Alendronate Sodium | Alendronate Sodium | 148 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 143 | 19 |
| Entresto | Sacubitril/Valsartan | 141 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 141 | 53 |
| Tresiba Flextouch U-100 | Insulin Degludec | 140 | 30 |
| Mirtazapine | Mirtazapine | 130 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 129 | 29 |
| Tresiba Flextouch U-200 | Insulin Degludec | 129 | 25 |
| Xarelto | Rivaroxaban | 129 | 21 |
| Lovastatin | Lovastatin | 127 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 125 | 28 |
| Fenofibrate | Fenofibrate Nanocrystallized | 116 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 114 | 19 |
| Warfarin Sodium | Warfarin Sodium | 113 | 12 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 109 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 108 | 86 |
| Levofloxacin | Levofloxacin | 108 | 80 |
| Ropinirole Hcl | Ropinirole Hcl | 104 | 15 |
| Klor-Con M20 | Potassium Chloride | 102 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 100 | 21 |
| Spironolactone | Spironolactone | 98 | 21 |
| Midodrine Hcl | Midodrine Hcl | 95 | 16 |
| Januvia | Sitagliptin Phosphate | 94 | 17 |
| Nystatin | Nystatin | 94 | 41 |
| Naproxen | Naproxen | 90 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 88 | 38 |
| Lamotrigine | Lamotrigine | 88 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 87 | suppressed |
| Topiramate | Topiramate | 86 | 11 |
| Kerendia | Finerenone | 85 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 84 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 84 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 83 | 13 |
| Methadone Hcl | Methadone Hcl | 81 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 80 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 79 | 43 |
| Valsartan | Valsartan | 79 | 15 |
| Novolog Flexpen | Insulin Aspart | 75 | 22 |
| Symbicort | Budesonide/Formoterol Fumarate | 75 | 17 |
| Bupropion Xl | Bupropion Hcl | 74 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 74 | 21 |
| Diazepam | Diazepam | 72 | suppressed |
| Fentanyl | Fentanyl | 72 | 11 |
| Fluconazole | Fluconazole | 71 | 31 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 71 | 41 |
| Atenolol | Atenolol | 68 | 14 |
| Baclofen | Baclofen | 67 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 67 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 67 | 12 |
| Sucralfate | Sucralfate | 67 | 18 |
| Clonidine Hcl | Clonidine Hcl | 66 | suppressed |
| Brilinta | Ticagrelor | 65 | suppressed |
| Creon | Lipase/Protease/Amylase | 65 | suppressed |
| Ibuprofen | Ibuprofen | 65 | 21 |
| Aripiprazole | Aripiprazole | 63 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 63 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 62 | suppressed |
| Finasteride | Finasteride | 57 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 57 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 56 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 13 |
| Methylphenidate Hcl | Methylphenidate Hcl | 55 | suppressed |
| Cephalexin | Cephalexin | 54 | 36 |
| Colchicine | Colchicine | 54 | 15 |
| Levemir Flexpen | Insulin Detemir | 54 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 52 | suppressed |
| Hydrocortisone | Hydrocortisone | 52 | 11 |
| Metformin Hcl Er | Metformin Hcl | 52 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 51 | 13 |
| Clonidine | Clonidine | 51 | suppressed |
| Estradiol | Estradiol | 50 | 11 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 50 | suppressed |
| Levemir | Insulin Detemir | 49 | suppressed |
| Digoxin | Digoxin | 48 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 22 |
| Alcohol Pads | Alcohol Antiseptic Pads | 46 | 23 |
| Gemtesa | Vibegron | 46 | suppressed |
| Ondansetron Odt | Ondansetron | 46 | 16 |
| Methotrexate | Methotrexate Sodium | 45 | suppressed |
| Ramipril | Ramipril | 45 | suppressed |
| Ranolazine Er | Ranolazine | 45 | suppressed |
| Chlorthalidone | Chlorthalidone | 44 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 42 | suppressed |
| Glipizide | Glipizide | 42 | suppressed |
| Lansoprazole | Lansoprazole | 40 | 11 |
| Propranolol Hcl | Propranolol Hcl | 40 | suppressed |
| Temazepam | Temazepam | 40 | 11 |
| Torsemide | Torsemide | 40 | suppressed |
| Bumetanide | Bumetanide | 39 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | suppressed |
| Latanoprost | Latanoprost | 37 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 37 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 36 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 35 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Fenofibrate | Fenofibrate | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 28 |
| Lidocaine | Lidocaine | 32 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 32 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 19 |
| Anastrozole | Anastrozole | 29 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 29 | suppressed |
| Methimazole | Methimazole | 28 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 27 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 26 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 26 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 26 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 26 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Belsomra | Suvorexant | 23 | suppressed |
| Humalog | Insulin Lispro | 23 | suppressed |
| Rexulti | Brexpiprazole | 23 | suppressed |
| Ubrelvy | Ubrogepant | 23 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 21 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 20 | 16 |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Movantik | Naloxegol Oxalate | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 19 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Novolog | Insulin Aspart | 18 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 18 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 18 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 16 | suppressed |
| Lyrica | Pregabalin | 16 | suppressed |
| Modafinil | Modafinil | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Estradiol (Once Weekly) | Estradiol | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Trimethoprim | Trimethoprim | 15 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 14 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 14 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Calcium Acetate | Calcium Acetate | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Isentress | Raltegravir Potassium | 13 | suppressed |
| Levetiracetam Er | Levetiracetam | 13 | suppressed |
| Lopinavir-Ritonavir | Lopinavir/Ritonavir | 13 | suppressed |
| Novolin R | Insulin Regular, Human | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | 11 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Cartia Xt | Diltiazem Hcl | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Cholestyramine Light | Cholestyramine | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $854.29 · 47 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, BREZTRI, CREON, ELIQUIS, FARXIGA, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VIBERZI, VOQUEZNA, XYOSTED | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error